S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02913066 |
Recruitment Status : Unknown
Verified June 2017 by Xiaobo Du, Mianyang Central Hospital.
Recruitment status was: Recruiting
First Posted : September 23, 2016
Last Update Posted : June 16, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Will meet the inclusion criteria of patients with esophageal squamous cell carcinoma, divided into 2 groups randomly:
Experimental group: radiotherapy combined with S-1 chemotherapy.
Control group: radiotherapy combined with S-1 chemotherapy and cisplatin.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Esophageal Squamous Cell Carcinoma | Other: S-1 concurrent radiotherapy Other: S-1 plus Cisplatin concurrent radiotherapy | Phase 2 |
Will meet the inclusion criteria of patients with unresectable esophageal squamous cell carcinoma, divided into 2 groups randomly:
Experimental group: radiotherapy combined with S-1 chemotherapy;
control group: radiotherapy combined with S-1 chemotherapy for first to 14 days and 29 ~ 42 days, plus cisplatin first 1~ 4 days and 29 ~ 33 days. Using IMRT radiotherapy.
Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, or S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.
Primary Outcome Measure is complete remission rate.
Secondary Outcome Measures are overall survival (OS) and Progression-Free-Survival (PFS) and toxicity.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 88 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma |
Study Start Date : | September 2016 |
Estimated Primary Completion Date : | March 2019 |
Estimated Study Completion Date : | March 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Single drug
S-1 concurrent Radiotherapy
|
Other: S-1 concurrent radiotherapy
Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~33 planning target volume times, 60~66 Gray/28~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1~ 14 days, 21 days for a cycle. |
Active Comparator: Double drug
S-1 plus cisplatin concurrent Radiotherapy
|
Other: S-1 plus Cisplatin concurrent radiotherapy
Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~30 planning target volume times, Gross tumor volume of primary tumor60~66 Gray/28~33), synchronous chemotherapy S-1 70 mg/m2 1~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle. |
- Complete Remission Rate (CR) [ Time Frame: Three months after radiotherapy finished ]Complete response rate of primary tumor which will be measured by endoscopy and computer tomography
- Overall Survival (OS) [ Time Frame: Two years after adjuvant chemotherapy finished ]The time from treatment completion to patient death
- Progression-Free-Survival (PFS) [ Time Frame: Two years after adjuvant chemotherapy finished ]The time from treatment completion to disease progression
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 75 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histology or cytology confirmed esophageal squamous cell carcinoma.
- There are measurable lesions in the RECIST standard.
- American Joint Committee on Cancer/Union Internationale Contre le Cancer esophageal cancer staging (Sixth Edition) clinical stage II a~ IV B period.
- Age younger than 75 years old.
- Eastern Cooperative Oncology Group physical status score was 0 ~ 1.
- No esophageal perforation and active esophageal bleeding, no obvious trachea, thoracic major vascular invasion.
- Chest chemotherapy and radiotherapy, immunotherapy or biologic therapy have not been performed before.
- Serum hemoglobin is<100g/L, platelet>100 * 109/L,Absolute neutrophil count>1.5 * 109/L.
- Cr≤1.25 upper normal limit or CCr≥60 mL/min.
- Serum bilirubin ≤1.5 times upper normal limit, Aspartate transaminase (SGOT) and Alanine aminotransferase (SGPT) ≤ 2.5 times upper normal limit,Alkaline phosphatase≤ 5 times upper normal limit.
- A history of interstitial pneumonia and interstitial pneumonia.
- FEV1>0.8 liters.
- Patients or family members signed a formal informed consent.
Exclusion Criteria:
- Prior to the start of the trial had received thoracic radiotherapy, chemotherapy or surgical resection of esophageal cancer.
- Primary lesions were multifocal esophageal cancer patients, the lower bound of esophageal primary lesions was less than 3cm.
- Patients with severe cardiovascular or pulmonary disease, interstitial pneumonia or a history of interstitial pneumonia.
- Patients with distant metastases.
- There were obvious esophageal ulcer, chest and back with moderate pain, and the symptoms of esophageal perforation.
- Can't understand the test requirements, or patients may not comply with the requirements of the test.
- There are other malignant lesion patients, but can cure skin cancer (non melanoma), cervical carcinoma in situ or malignant disease cured except for more than 5 years.
- An allergic reaction known to have 3 or 4 levels of any treatment.
- Had participated in other clinical trials in the past 30 days.
- The researchers believe that some of the obvious diseases that should be excluded from this study are excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02913066
Contact: Bo Du X, Doctor | +8613550822229 | duxiaobo2005@126.com | |
Contact: Xue W Y, Student | +8615181958867 | 532995900@qq.com |
China, Sichaung | |
Xiaobo du | Recruiting |
Mianyang, Sichaung, China, 621000 | |
Contact: Xaiobo Du, MD +86 08162230478 duxiaobo2005@126.com |
Principal Investigator: | Bo Du X, Doctor | Mianyang Central Hospital |
Responsible Party: | Xiaobo Du, Principal Investigator, Mianyang Central Hospital |
ClinicalTrials.gov Identifier: | NCT02913066 |
Other Study ID Numbers: |
XDu |
First Posted: | September 23, 2016 Key Record Dates |
Last Update Posted: | June 16, 2017 |
Last Verified: | June 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Carcinoma Carcinoma, Squamous Cell Esophageal Squamous Cell Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Esophageal Neoplasms Gastrointestinal Neoplasms |
Digestive System Neoplasms Neoplasms by Site Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Cisplatin Antineoplastic Agents |